VBI Vaccines Revenue and Competitors

Boston, MA USA

Location

$380.7M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • VBI Vaccines's estimated annual revenue is currently $15.7M per year.(i)
  • VBI Vaccines's estimated revenue per employee is $155,000
  • VBI Vaccines's total funding is $380.7M.

Employee Data

  • VBI Vaccines has 101 Employees.(i)
  • VBI Vaccines grew their employee count by -16% last year.

VBI Vaccines's People

NameTitleEmail/Phone
1
President & CEOReveal Email/Phone
2
Chief Financial Officer & Head Corporate DevelopmentReveal Email/Phone
3
VP - Market Access & Contract OperationsReveal Email/Phone
4
SVP Business DevelopmentReveal Email/Phone
5
VP For Immunization Policy, Government Affairs, and AdvocacyReveal Email/Phone
6
Head EU Commercial OperationsReveal Email/Phone
7
Director, Biologics CMC and Analytical DevelopmentReveal Email/Phone
8
Executive Assistant and Office ManagerReveal Email/Phone
9
Manager, Quality AssuranceReveal Email/Phone
10
Enterprise IT ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is VBI Vaccines?

VBI Vaccines Inc. (Nasdaq: VBIV) is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI is advancing the prevention and treatment of hepatitis B with the only 3-antigen hepatitis B vaccine, Sci-B-Vac®, which is approved for use and commercially available in Israel, and recently completed its Phase 3 program in the U.S., Europe, and Canada, and with an immunotherapeutic in development for a functional cure for chronic hepatitis B. VBI's enveloped virus-like particle (eVLP) platform technology enables development of eVLPs that closely mimic the target virus to elicit a potent immune response. VBI's lead eVLP programs include a vaccine immunotherapeutic candidate targeting glioblastoma (GBM), a prophylactic cytomegalovirus (CMV) vaccine candidate, and a prophylactic pan-coronavirus vaccine candidate. VBI is headquartered in Cambridge, MA, with research operations in Ottawa, Canada, and research and manufacturing facilities in Rehovot, Israel. To learn more, visit: www.vbivaccines.com News and Insights: www.vbivaccines.com/wire/ Investors: www.vbivaccines.com/investors/ Job Opportunities: www.vbivaccines.com/about/careers/

keywords:N/A

$380.7M

Total Funding

101

Number of Employees

$15.7M

Revenue (est)

-16%

Employee Growth %

N/A

Valuation

N/A

Accelerator

VBI Vaccines News

2022-04-20 - Where Will VBI Vaccines Inc (VBIV) Stock Go Next After It Has Fallen 9.68% in a Week?

Overall market sentiment has been down on VBI Vaccines Inc (VBIV) stock lately. VBIV receives a Bearish rating from InvestorsObserver Stock...

2022-04-13 - VBI Vaccines announces progress from coronavirus programme

Pre-clinical research from VBI Vaccines has demonstrated an encouraging ability to boost and broaden the immune response against the...

2022-04-06 - VBI Vaccines Announces New Data and Progress of VBI-2900 ...

Through its innovative approach to virus-like particles (“VLPs”), including a proprietary enveloped VLP (“eVLP”) platform technology, VBI...

2021-11-08 - VBI Vaccines Announces Third Quarter 2021 Financial Results and Provides Corporate Update - Form 8-K

VBI Vaccines Announces Third Quarter 2021 Financial Results and Provides Corporate Update - Hepatitis B (HBV) : ● Prophylactic : FDA and EMA regulatory review of VBI's 3-antigen prophylactic HBV vaccine candidate ongoing - U.S. PDUFA target action date November 30, 2021 ● On November 3, t ...

2021-11-01 - VBI Vaccines Announces e-Poster Presentation of 3-Antigen Prophylactic - Form 8-K

VBI Vaccines Announces e-Poster Presentation of 3-Antigen Prophylactic Hepatitis B Vaccine Data at The Liver Meeting® 2021 CAMBRIDGE, Mass. (November 1, 2021) - VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and tr ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$22M1011%$478.3M
#2
$15.7M10163%$203M
#3
$14.6M1016%$28.8M
#4
$15.7M101-6%N/A
#5
$23.9M102-3%N/A